Currently out of the existing stock ratings of Charles Duncan, 466 are a BUY (92.64%), 35 are a HOLD (6.96%), 2 are a SELL (0.4%).

Charles Duncan

Work Performance Price Targets & Ratings Chart

Analyst Charles Duncan, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 52.41% that have a potential upside of 48.99% achieved within 368 days.

Charles Duncan’s has documented 956 price targets and ratings displayed on 76 stocks. The coverage is on Healthcare, Industrials, Technology, Basic Materials sectors.

Most recent stock forecast was given on SLDB, Solid Biosciences LLC at 17-Jun-2025.

Wall Street Analyst Charles Duncan

Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS) at 7/24/2023. The price target of $145 was fulfilled within 4 days with a profit of $35.33 (32.21%) receiving and performance score of 80.54.

Average potential price target upside

of $1352 (99.5%) on CNAT (CONATUS PHARMACEUTICALS).
of $73.25 (81.12%) on ADVM (ADVERUM BIOTECHNOLOGIES).
of $59.93 (69.37%) on BNOX (BIONOMICS LTD ADR).

ACAD ACADIA Pharmaceuticals AVXL Anavex Life Sciences Corp AXSM Axsome Therapeutics BCRX BioCryst Pharmaceuticals BHVN Biohaven Pharmaceutical Holding Co Ltd CARA Cara Therapeutic CLVS Clovis Oncology CMPS Compass Pathways Plc CORT Corcept Therapeutics CPRX Catalyst Pharmaceuticals CYTK Cytokinetics GERN Geron HALO Halozyme Therapeutics INO Inovio Pharmaceuticals ITCI Intracellular Th NBIX Neurocrine Biosciences NVAX Novavax OREX Orexigen Therapeutics PRTA Prothena plc RETA Reata Pharmaceuticals SAVA Cassava Sciences SGMO Sangamo Therapeutics VNDA Vanda Pharmaceuticals VYGR Voyager Therapeutics OTIC Otonomy ACOR Acorda Therapeutics AIMT Aimmune Therapeutics APTX Aptinyx AXON Axon Enterprise LUCD Lucid Diagnostics LUMO Lumos Pharma VXRT Vaxart CLNN Clene SEEL Seelos Therapeutics MRTX Mirati Ther ZYNE Zynerba Pharmaceuticals ADVM Adverum Biotechnologies CERE Cerevel Therapeutics Holdings DNLI Denali Therapeutics STOK Stoke Therapeutics BNOX Bionomics Ltd ADR CTIC CTi Biopharma Corp FENC Fennec Pharmaceuticals KRTX Karuna Therapeutics MRNS Marinus Pharmaceuticals ONTX Onconova Therapeutics OVID Ovid Therapeutics ZSAN Zosano Pharma Corp CRNX Crinetics Pharmaceuticals KALV Kalvista Pharmaceuticals BIVI Biovie CRDL Cardiol Therapeutics HRMY Harmony Biosciences Holdings MNMD Mind Medicine XENE Xenon Pharmaceuticals CYBN Cybin ALKS Alkermes Plc ATAI ATAI Life Sciences BV JAZZ Jazz Pharmaceuticals PLC ALDR Alder BioPharmaceuticals ARCT Arcturus Therapeutics Holdings CNAT Conatus Pharmaceuticals DCPH Deciphera Pharmaceuticals LLC MITO Stealth BioTherapeutics Corp VBLT Vascular Biogenics Ltd VTVT vTv Therapeutics SLDB Solid Biosciences LLC AI C3 Ai AP Ampco-Pittsburgh BN Brookfield Corp CAR Avis Budget Group CE Celanese ECOR Electrocore LLC IT Gartner JNJ Johnson & Johnson ORMP Oramed Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ami Fadia (NEEDHAM)